Primary systemic treatment and concomitant low dose radiotherapy for breast cancer: Final results of a prospective phase II study

Autor: Gianluca Franceschini, Vincenzo Valentini, Anna Sapino, Giuseppe Roberto D' Agostino, Luigia Nardone, Maria Carmen De Santis, Barbara Diletto, Antonino Mulè, Enida Bufi, Paolo Belli, Daniela Terribile
Jazyk: angličtina
Rok vydání: 2014
Předmět:
medicine.medical_treatment
Settore MED/18 - CHIRURGIA GENERALE
Phases of clinical research
Docetaxel
Gastroenterology
Polyethylene Glycols
Breast cancer
Antineoplastic Combined Chemotherapy Protocols
Ductal
Anthracyclines
Prospective Studies
Breast
Preoperative treatment
Dose Fractionation
Mastectomy
Adjuvant
Settore MED/36 - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIA
Tumor Regression Grade
Radiation
Carcinoma
Ductal
Breast
Primary systemic therapy
General Medicine
Chemoradiotherapy
Middle Aged
Primary tumor
Low dose radiotherapy
Treatment Outcome
Female
Taxoids
medicine.drug
Adult
medicine.medical_specialty
Anthracycline
Antineoplastic Agents
Breast Neoplasms
Drug Administration Schedule
Lobular
Internal medicine
medicine
Humans
Aged
Neoplasm Staging
Chemotherapy
business.industry
Carcinoma
Chemoradiotherapy
Adjuvant
medicine.disease
Surgery
Carcinoma
Lobular
Doxorubicin
Concomitant
Dose Fractionation
Radiation
business
Follow-Up Studies
Popis: Background To evaluate the efficacy of preoperative low dose fractionated radiotherapy (LD-FRT) and chemotherapy in breast cancer. Materials and methods Patients with stage IIA–IIIA breast cancer, received LD-FRT (0.40 Gy bid, on day 1 and 2, for 6 cycles) to primary tumor volume and concurrent chemotherapy with non-pegylated liposomal anthracycline and docetaxel. Pathological response was assessed by Mandard Tumor Regression Grade (TRG). We evaluated the pathological major response rate (PMRR) as TRG1 and TRG2. The expected outcome was a PMRR of 60%. The accrual was determined by the single proportion powered analysis ( α = 0.05, power = 0.8). Results Twentyone patients were enrolled. No grade 2–4 acute skin and hematological toxicity was observed. TRG1 was obtained in 3 patients (14.3%), TRG2 in 4 patients (19%). The PMRR was 33.3%; it does not concur with the expected result, but is similar to that of chemotherapy alone. According to molecular subtype, 2/11 luminal A patients and 4/6 luminal B patients obtained a PMRR to preoperative treatment (35.3%); 1/4 basal like patients reported TRG1 (25%). Conclusions LD-FRT concomitant with primary systemic treatment has a good toxicity profile. The response rate is consistent with that of chemotherapy alone, and suggests different interactions between low dose radiotherapy and molecular subtypes. Additional investigations are planned.
Databáze: OpenAIRE
Externí odkaz: